Skip to main content

Table 2 Laboratory findings of patients with macrophage activation syndrome

From: Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis

 

Tocilizumab

Historic cohort

Full-blown (n = 2)

Possible (n = 10)

All (n = 12)

Full-blown (n = 10)

Possible (n = 8)

All (n = 18)

Ferritin (ng/ml)

12,645

587**

664***

11,035

8518**

9235***

4155–21,135

402–2330

410–3785

6585–32,644

3390–11,833

5559–18,710

Platelets (× 104/mm3)

12.4

11.7****

11.7***

14.5

21.9****

18.9***

7.6–17.2

7.7–13.1

7.7–13.3

12.1–18.5

20.2–32.2

13.3–21.8

AST (IU/l)

666

119

161

296

63

89

382–949

61–290

63–438

78–681

53–92

61–425

TG (mg/dl)

362

108*

113*

279

148*

214*

149–574

91–132

94–150

192–298

141–213

143–285

Fibrinogen (mg/dl)

116

118****

118****

281

319****

294****

80–152

102–172

97–163

217–292

302–482

240–362

CRP (mg/dl)

3.1

0.03****

0.03****

7.5

9.6****

7.6****

0.0–6.1

0.0–0.6

0.0–6.1

3.3–12.9

4.7–15.1

3.7–13.6

  1. Median values and IQR were shown. * = p < 0.05; ** = p < 0.01; *** = p < 0.001; **** = p < 0.0001; AST Aspartic aminotransferase, TG Triglyceride, CRP C reactive protein
Back to article page

Pediatric Rheumatology

ISSN: 1546-0096